A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma
Objective: To evaluate direct asthma-related costs in Swedish primary care in a real-life setting. Design: 12-month open-label study. Setting: Swedish primary care in a real-life setting. Participants: 1776 patients with persistent asthma. Interventions: Patients with persistent asthma were randomised to one of three treatments: a free adjustable combination of budesonide (100-400 mu g/inhalation)
